Prospective Cohort of Opiate Dependent Patients on Buprenorphine/Naloxone for Maintenance
NCT ID: NCT00622596
Last Updated: 2016-08-24
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
200 participants
INTERVENTIONAL
2003-10-31
2008-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Buprenorphine and Integrated HIV Care
NCT00317460
Buprenorphine Maintenance for Opioid Addicts - 2
NCT00000203
Buprenorphine Maintenance vs. Detoxification in Prescription Opioid Dependence
NCT00555425
Buprenorphine and Integrated HIV Care Evaluation
NCT00124358
Effects of Buprenorphine/Naloxone in Treating Opioid Dependent Individuals Who Are Maintained on Methadone
NCT00000243
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Mobile Access to Buprenorphine
High risk populations accessing a mobile health care system can obtain Buprenorphine for treatment.
Mobile Access
Subjects would access buprenorphine through mobile access. On day 1: 8 mg of buprenorphine, then on Day 2: 16 mg daily of buprenorphine sublingually.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Mobile Access
Subjects would access buprenorphine through mobile access. On day 1: 8 mg of buprenorphine, then on Day 2: 16 mg daily of buprenorphine sublingually.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* At high risk for HIV (IV drug use, commercial sex worker, partner of HIV+)
* Mental Health (unmanaged or diagnosed mental illness)
Exclusion Criteria
* Opiate use due to pain management issues only (present or past)
* Non-IDU
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Yale University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Frederick L Altice, MD
Role: PRINCIPAL_INVESTIGATOR
Yale University School of Medicine/AIDS Program
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Yale University School of Medicine
New Haven, Connecticut, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
0504027630
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.